PE20181038A1 - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h - Google Patents
Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132hInfo
- Publication number
- PE20181038A1 PE20181038A1 PE2018000133A PE2018000133A PE20181038A1 PE 20181038 A1 PE20181038 A1 PE 20181038A1 PE 2018000133 A PE2018000133 A PE 2018000133A PE 2018000133 A PE2018000133 A PE 2018000133A PE 20181038 A1 PE20181038 A1 PE 20181038A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- isocitrate dehydrogenase
- acid
- idh1
- mutated isocitrate
- Prior art date
Links
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 title 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102200069690 rs121913500 Human genes 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 3
- 235000011087 fumaric acid Nutrition 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un aducto formado por el acido (2E)-but-2-enedioico y un acido 3-(2-{[4-4-trifluorometoxi)fenil]amino}-1-[(1R,5R)-3,3,5-trimetilciclohexil]-1H-benzimidazol-5-il)propanoico que comprende una molecula de acido fumarico a cuatro moleculas de acido 3-(2-{[4-4-trifluorometoxi)fenil]amino}-1-[(1R,5R)-3,3,5-trimetilciclohexil]-1H-benzimidazol-5-il)propanoico. Dicho aducto en su forma cristalina posee picos maximos en un difractograma de rayos X (2 theta) tales como 5,4; 6,8; 10,2; 10,3; 10,8; 11,1; 16,8 y 21,6. La presente invencion es util para el tratamiento y profilaxis de tumores
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15178419 | 2015-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181038A1 true PE20181038A1 (es) | 2018-07-03 |
Family
ID=53758092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000133A PE20181038A1 (es) | 2015-07-27 | 2016-07-22 | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10344004B2 (es) |
| EP (1) | EP3328837B1 (es) |
| JP (1) | JP6804516B2 (es) |
| KR (1) | KR20180030789A (es) |
| CN (1) | CN107810181B (es) |
| AR (1) | AR105493A1 (es) |
| AU (1) | AU2016300980B2 (es) |
| BR (1) | BR112018001534A2 (es) |
| CA (1) | CA2993473A1 (es) |
| CL (1) | CL2018000249A1 (es) |
| CO (1) | CO2018000793A2 (es) |
| CR (1) | CR20180053A (es) |
| CU (1) | CU20180014A7 (es) |
| DO (1) | DOP2018000027A (es) |
| EA (1) | EA201890386A1 (es) |
| EC (1) | ECSP18006465A (es) |
| ES (1) | ES2860693T3 (es) |
| HK (1) | HK1252449A1 (es) |
| IL (1) | IL256024A (es) |
| MX (1) | MX2018001205A (es) |
| NI (1) | NI201800014A (es) |
| PE (1) | PE20181038A1 (es) |
| SV (1) | SV2018005621A (es) |
| TN (1) | TN2018000038A1 (es) |
| TW (1) | TW201708193A (es) |
| WO (1) | WO2017016992A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201605810WA (en) | 2014-02-11 | 2016-08-30 | Bayer Pharma AG | Benzimidazol-2-amines as midh1 inhibitors |
| WO2015121209A1 (en) | 2014-02-11 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| EP3209660B1 (en) | 2014-10-23 | 2020-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors |
| EP3303302B1 (en) | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| JP6824952B2 (ja) | 2015-07-07 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール |
| WO2017009325A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201718513A (zh) | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法 |
| WO2019015672A1 (zh) * | 2017-07-21 | 2019-01-24 | 南京明德新药研发股份有限公司 | 吡啶并咪唑类化合物及其应用 |
| WO2019025256A1 (en) | 2017-08-01 | 2019-02-07 | Bayer Aktiengesellschaft | COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS |
| CN108948205B (zh) * | 2018-07-13 | 2021-09-28 | 北京金岱生物科技有限公司 | 抗idh1r132h单克隆抗体及其应用 |
| TWI760017B (zh) * | 2019-12-23 | 2022-04-01 | 大陸商昆藥集團股份有限公司 | 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法 |
| US20230270814A1 (en) | 2020-07-21 | 2023-08-31 | Daiichi Sankyo Company, Limited | Combination pharmaceutical of temozolomide and mutant idh1 enzyme inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010151441A1 (en) * | 2009-06-23 | 2010-12-29 | Translational Genomics Research Institute | Benzamide derivatives |
| US9012464B2 (en) * | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| AP3907A (en) * | 2011-09-27 | 2016-11-23 | Novartis Ag | 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| WO2015121209A1 (en) | 2014-02-11 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| SG11201605810WA (en) * | 2014-02-11 | 2016-08-30 | Bayer Pharma AG | Benzimidazol-2-amines as midh1 inhibitors |
| EP3209660B1 (en) * | 2014-10-23 | 2020-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors |
| CN107108522B (zh) | 2014-10-23 | 2020-12-01 | 德国癌症研究中心 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
| EP3303302B1 (en) | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| JP6824952B2 (ja) | 2015-07-07 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール |
| WO2017009325A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| EP3121166A1 (en) * | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201718513A (zh) * | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法 |
-
2016
- 2016-07-14 TW TW105122262A patent/TW201708193A/zh unknown
- 2016-07-22 CA CA2993473A patent/CA2993473A1/en not_active Abandoned
- 2016-07-22 ES ES16741332T patent/ES2860693T3/es active Active
- 2016-07-22 KR KR1020177036977A patent/KR20180030789A/ko not_active Withdrawn
- 2016-07-22 PE PE2018000133A patent/PE20181038A1/es unknown
- 2016-07-22 BR BR112018001534A patent/BR112018001534A2/pt not_active Application Discontinuation
- 2016-07-22 CU CUP2018000014A patent/CU20180014A7/es unknown
- 2016-07-22 WO PCT/EP2016/067477 patent/WO2017016992A1/en active Application Filing
- 2016-07-22 EA EA201890386A patent/EA201890386A1/ru unknown
- 2016-07-22 CR CR20180053A patent/CR20180053A/es unknown
- 2016-07-22 CN CN201680038633.9A patent/CN107810181B/zh not_active Expired - Fee Related
- 2016-07-22 MX MX2018001205A patent/MX2018001205A/es unknown
- 2016-07-22 US US15/748,014 patent/US10344004B2/en not_active Expired - Fee Related
- 2016-07-22 AU AU2016300980A patent/AU2016300980B2/en not_active Ceased
- 2016-07-22 JP JP2018504187A patent/JP6804516B2/ja not_active Expired - Fee Related
- 2016-07-22 EP EP16741332.7A patent/EP3328837B1/en active Active
- 2016-07-22 TN TNP/2018/000038A patent/TN2018000038A1/en unknown
- 2016-07-27 AR ARP160102274A patent/AR105493A1/es unknown
-
2017
- 2017-11-30 IL IL256024A patent/IL256024A/en unknown
-
2018
- 2018-01-26 SV SV2018005621A patent/SV2018005621A/es unknown
- 2018-01-26 DO DO2018000027A patent/DOP2018000027A/es unknown
- 2018-01-26 EC ECIEPI20186465A patent/ECSP18006465A/es unknown
- 2018-01-26 CO CONC2018/0000793A patent/CO2018000793A2/es unknown
- 2018-01-26 NI NI201800014A patent/NI201800014A/es unknown
- 2018-01-26 CL CL2018000249A patent/CL2018000249A1/es unknown
- 2018-09-13 HK HK18111750.7A patent/HK1252449A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SV2018005621A (es) | 2018-12-05 |
| HK1252449A1 (zh) | 2019-05-24 |
| TN2018000038A1 (en) | 2019-07-08 |
| CO2018000793A2 (es) | 2018-05-10 |
| CN107810181B (zh) | 2021-06-22 |
| AU2016300980B2 (en) | 2020-12-24 |
| US20180222870A1 (en) | 2018-08-09 |
| EP3328837B1 (en) | 2021-01-06 |
| AR105493A1 (es) | 2017-10-11 |
| ES2860693T3 (es) | 2021-10-05 |
| MX2018001205A (es) | 2018-04-24 |
| CU20180014A7 (es) | 2018-06-05 |
| CA2993473A1 (en) | 2017-02-02 |
| BR112018001534A2 (pt) | 2018-09-11 |
| EA201890386A1 (ru) | 2018-08-31 |
| AU2016300980A1 (en) | 2017-12-21 |
| JP6804516B2 (ja) | 2020-12-23 |
| DOP2018000027A (es) | 2018-02-28 |
| TW201708193A (zh) | 2017-03-01 |
| EP3328837A1 (en) | 2018-06-06 |
| WO2017016992A1 (en) | 2017-02-02 |
| KR20180030789A (ko) | 2018-03-26 |
| CN107810181A (zh) | 2018-03-16 |
| US10344004B2 (en) | 2019-07-09 |
| CL2018000249A1 (es) | 2018-07-06 |
| NI201800014A (es) | 2018-09-06 |
| JP2018521095A (ja) | 2018-08-02 |
| CR20180053A (es) | 2018-03-20 |
| ECSP18006465A (es) | 2018-04-30 |
| IL256024A (en) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181038A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| CL2019001066A1 (es) | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) | |
| MX390726B (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen tales compuestos. | |
| CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CO2018003828A2 (es) | Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| CU20150095A7 (es) | Pirimidinas fusionadas sustituidas con trifluorometilo | |
| CL2017002813A1 (es) | Proceso para preparar 4-amino-piridazinas | |
| GT201300215A (es) | Inhibidores de glucosilceramida sintasa | |
| CU20140055A7 (es) | Procedimiento de preparación de 5- fluoro- 1h-pirazolopiridinas sustituidas | |
| PE20141303A1 (es) | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| CR20140305A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios | |
| CO7121335A2 (es) | Procedimiento mejorado para la producción de hematita finamente dividida y de pigmentos de óxido de hierro rojos | |
| BR112013028187A2 (pt) | processo para produzir olefinas | |
| JOP20130304B1 (ar) | مستحضر وصيغة تشتمل على مثبط mek | |
| CL2018002583A1 (es) | Derivado de morfolina | |
| UY35312A (es) | Ácidos indaniloxidihidrobenzofuranilacéticos como agonistas del receptor acoplado a la proteína g40 | |
| BR112013025776A2 (pt) | método de formação de um substrato estável para uma superfície esportiva de uma quadra de esportes; substrato para uma superfície esportiva de uma quadra de esportes; quadra de esportes | |
| CO6341612A2 (es) | Compuestos novedosos de fenilamino-isonicotinamina | |
| BR112014014939A2 (pt) | composição de tratamento de sementes | |
| MX2016004230A (es) | Composiciones y metodos para inhibir la expresion del gen lect2. | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| BR112016010862A8 (pt) | formas mórficas de ésteres de hexadeciloxipropil-fosfonato, seu método de preparo e composição compreendendo a dita forma mórfica | |
| MX2015015151A (es) | Metodo para producir 4-hidroxi-4-metil-tetrahidropiranos 2-sustituidos, donde dicho proceso usa reciclado. | |
| BR112014009760A8 (pt) | análogos de ácido siálico |